CNMD is the ticker symbol for CONMED Corp, a publicly traded Healthcare sector company listed on NYSE. 13F Pro tracks CNMD with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is CNMD a good stock to buy?

13F Pro's AI ranking engine scores CNMD at 47.6/100, ranked #1,788 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for CNMD is available at https://13fpro.ai/company/CNMD. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source CNMD data?

All CONMED Corp fundamentals and ownership data come directly from SEC EDGAR. CONMED Corp files with the SEC under CIK 816956. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

CONMED Corp CNMD

NYSESmall CapHealthcare

13F Pro quality score

Rank #1,788 of 2,925

Why it scores 48 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$343.49M

Quarter to Jun 30

Net income

$23.07M

Quarter to Jun 30

Free cash flow

$34.16M

Quarter to Jun 30

Operating margin

10.6%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$1.26B total

BlackRock, Inc.

$157.78M-72.5%

EARNEST PARTNERS LLC

$82.00M-2.5%

VANGUARD PORTFOLIO MANAGEMENT LLC

$71.64M+5.4%

OAKTREE CAPITAL MANAGEMENT LP

$52.46M+48.2%

FULLER & THALER ASSET MANAGEMENT, INC.

$51.71M-3.8%

STATE STREET CORP

$46.39M-92.1%

VANGUARD CAPITAL MANAGEMENT LLC

$44.37M-2.0%

BANK OF AMERICA CORP /DE/

$43.90M-4.4%

DIMENSIONAL FUND ADVISORS LP

$43.12M-5.4%

SEI INVESTMENTS CO

$32.34M-1.6%

Calamos Advisors LLC

$29.59M0.0%

Invenomic Capital Management LP

$27.56M-9.9%

Capital Research Global Investors

$26.96M-11.0%

GEODE CAPITAL MANAGEMENT, LLC

$25.87M+6.4%

TWO SIGMA INVESTMENTS, LP

$23.86M-6.8%

Allspring Global Investments Holdings, LLC

$20.26M+6.1%

COOKE & BIELER LP

$18.77M-41.9%

PARADIGM CAPITAL MANAGEMENT INC/NY

$17.62MNew

GOLDMAN SACHS GROUP INC

$16.25M+69.9%

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

$15.61M+13.8%

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

$15.42M-1.6%

SILVERCREST ASSET MANAGEMENT GROUP LLC

$14.45M-31.9%

AMERIPRISE FINANCIAL INC

$14.28M-5.2%

LSV ASSET MANAGEMENT

$13.17M+2995.4%

TORONTO DOMINION BANK

$12.68M+2069.4%

See all 259 institutional holders →

What's Driving CNMD's Business? Latest 10-Q Breakdown

24/24 datapoints verified

AI-extracted from the 10-Q filed 2026-07-29 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

CONMED grew Q2 revenue 0.3% YoY to $343.5M on orthopedic strength (+8.2%), but general surgery declined 5.2% due to gastroenterology exit; gross margins expanded 250bps to 57.5%.

Biggest Revenue Drivers

General Surgery$191.2M-5.2% YoY

Decline primarily due to exit from gastroenterology product offerings, partially offset by AirSeal and smoke evacuation growth.

Orthopedic Surgery$152.3M+8.2% YoY

Growth in powered surgical instruments, sports medicine, visualization, and BioBrace product offerings.

Biggest Revenue Drivers

Total revenue: $343.5M+0.3% YoY

General Surgery$191.2M-5.2% YoY

Decline primarily due to exit from gastroenterology product offerings, partially offset by AirSeal and smoke evacuation growth.

Orthopedic Surgery$152.3M+8.2% YoY

Growth in powered surgical instruments, sports medicine, visualization, and BioBrace product offerings.

Largest Expense Items

Cost of Sales$146.0M-5.2% YoY

Decreased from $154.0M prior year; benefits from $8.5M IEEPA tariff refunds and favorable foreign exchange, partially offset by $6.9M charge for inventory and tooling discontinuation.

Selling and Administrative Expense$145.6M+7.0% YoY

Increased primarily due to $4.4M loss on gastroenterology business sale, $3.3M advisory services costs, $7.1M operational optimization consulting, and increased investment in growth drivers.

Research and Development Expense$15.5M+9.6% YoY

Increase driven by $1.1M costs to comply with EU Medical Device Regulations and increased investment in key growth drivers.

Interest Expense$7.9M+0.8% YoY

Weighted average interest rates increased to 2.84% from 2.80% YoY, offset by lower average debt outstanding.

Margins: Gross profit margins expanded 250 basis points to 57.5%, driven primarily by $8.5M IEEPA tariff refunds, favorable foreign exchange, and product mix, partially offset by $6.9M in inventory and tooling charges. Operating margin contracted to 10.6% from 11.1% YoY due to higher SG&A and R&D expenses relative to revenue.

Watch Items from the Filing

Gastroenterology exit reduced Q2 revenue by ~$20.6M YoY; gastro sales fell from $25.3M to $4.7M, with exit costs including $4.4M loss on business sale.
Outstanding convertible notes reduced to $154.0M principal after $645.2M repurchase in June 2026; maturity June 15, 2027 requires refinancing or conversion management.
General surgery segment declined 5.2% YoY and 6.2% YTD; excluding gastro exit, would still show ~0.4% decline, indicating underlying segment softness.
Biorez contingent consideration payments increased to $28.9M in H1 2026 from $14.1M in H1 2025; $33.2M liability remains as of June 30, 2026.
Debt increased materially: $450M Term A-2 Loan borrowed June 12, 2026, plus $193M revolving credit draw; total variable-rate debt ~$683M as of quarter-end.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Debt/Equity

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CNMD

Earnings Per Share

13fpro.ai/company/CNMD

Loading ratio trend…

CONMED Corp reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$1.4B	$47.1M	7.5%
FY 2024	10-K	$1.3B	$132.4M	15.3%
FY 2023	10-K	$1.2B	$64.5M	9.7%
FY 2022	10-K	$1.0B	$-80.6M	6.7%
FY 2021	10-K	$1.0B	$62.5M	10.9%
FY 2020	10-K	$862.5M	$9.5M	5.3%

About CONMED Corp (CNMD): stock profile, AI score and financials

CONMED Corp (CNMD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CNMD at 47.6/100 on a composite quality score built from its SEC filings, placing it at rank #1,788 of 2,925 stocks — the bottom half of the AI-ranked universe. CNMD scores in the top quartile across earnings quality (88.2). Areas of concern include institutional flow (22.8) and profitability (34.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CONMED Corp reports quarterly revenue of $343.5M, net income of $23.1M, an operating margin of 10.6%. Top institutional holders of CNMD by reported 13-F value include BlackRock, EARNEST PARTNERS, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. CNMD trades on the NYSE exchange and files with the SEC under CIK 816956. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CNMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CONMED Corp directly from SEC EDGAR.

SEC EDGAR: CIK 816956 →

CONMED Corp CNMD

Top Institutional Holders

What's Driving CNMD's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

CNMD key financials by period

CNMD insiders

About CONMED Corp (CNMD): stock profile, AI score and financials

CONMED Corp CNMD

Top Institutional Holders

What's Driving CNMD's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

CNMD key financials by period

Companies similar to CNMD

CNMD insiders

About CONMED Corp (CNMD): stock profile, AI score and financials